PropertyValue
?:abstract
  • The COVID-19 outbreak occurred in Wuhan, China, in December 2019 has aroused wide public concern Both 2019-nCoV and SARS-CoV belong to the coronaviridae family, and invade target cells through ACE2 So an in-depth understanding of ACE2 and a series of pathophysiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical manifestations and then deal with them timely In addition, ACE2 is a potential therapeutic target, according to this, we can find the corresponding treatment strategy This article explains the role of ACE2 in multiple organ damage caused by 2019-nCoV and SARS-CoV, and blockers targeting ACE2, and inflammation inhibitors, with a view to providing a basis for subsequent related research, diagnosis and treatment, and drug development Copyright © 2020 by the Chinese General Practice
is ?:annotates of
?:creator
?:journal
  • Chinese_General_Practice
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Searching Therapeutic Strategies of COVID-19 from Angiotensin-converting Enzyme 2:the Receptor of 2019-nCoV and SARS-CoV
?:type
?:who_covidence_id
  • #832018
?:year
  • 2020

Metadata

Anon_0  
expand all